GSK, IDRx

GSK to buy US biotech firm IDRx for up to $1.15 billion
(Reuters) -British drugmaker GSK said on Monday that it would pay up to $1.15 billion to buy Boston-based biopharmaceutical firm IDRx, which is developing a treatment for a rare type of tumour. IDRx,
GSK to buy Boston-based IDRx for $1.15 billion
GSK (NYSE:GSK) finalized the deal to acquire Boston-based, clinical-stage biopharmaceutical company—IDRx for a total of up to $1.15 billion cash consideration. Under the agreement signed by both companies,
JP Morgan 2025: GSK acquires IDRx in $1.15bn deal
IDRx’s lead candidate IDRX-42 is being investigated in a Phase I/IIb trial in patients with advanced gastrointestinal stromal tumours.
GSK Enters Agreement to Acquire IDRx, Inc.
GSK plc (LSE/NYSE: GSK) and IDRx, Inc. (IDRx) today announced that they have entered into an agreement under which GSK will acquire IDRx, a Boston-based, clinical-stage biopharmaceutical company dedicated to developing precision therapeutics for the treatment of GIST.
GSK confirms plan to buy cancer firm IDRx for $1bn
This morning, the UK pharma group confirmed it had signed an agreement to buy privately-held IDRx for $1 billion upfront, with another $150 million in payments to the biotech's shareholders if its pipeline delivered as expected.
Drugmaker GSK buys US firm focused on gastro cancer
British pharmaceutical company GSK on Monday said it had agreed to buy a US company that specializes in the treatment of rare gastrointestinal cancer GIST.
GSK to acquire IDRx for $1B upfront
GSK (GSK) and IDRx announced that they have entered into an agreement under which GSK will acquire IDRx. Under the agreement, GSK will pay $1B
GSK CEO on acquisition of biotech firm IDRx
Emma Walmsley, GSK CEO, joins 'Money Movers' to discuss the company's deal to acquire IDRx, the impact of Robert F. Kennedy Jr.'s administration position, and much more.
GSK to buy cancer-focused IDRx in $1 billion deal
Seeking to build up its cancer business, GSK said Monday it is buying the privately held U.S. biotech IDRx for $1 billion upfront.
BioSpace7h
GSK Targets Rare Cancer With $1B+ Acquisition of IDRx
The first major deal of JPM 2025 will give GSK a promising small molecule drug for gastrointestinal stromal tumors.
ENDPOINTS NEWS2h
GSK kicks off JPM deal­mak­ing with $1B+ buy­out of IDRx and its rare can­cer drug
Is the frenzy of JPM dealmaking finally underway? GSK announced Monday morning that it will acquire the privately-held ...
FierceBiotech13h
JPM25: Strategist GSK acquires IDRx for $1B in hopes of bringing GIST patients new standard of care
In a deal worth up to $1.15 billion, GSK is acquiring precision medicine biotech IDRx and its phase 3-ready gastrointestinal ...
GSK CEO Optimistic About Dealmaking, New Trump Administration
GSK Plc’s Chief Executive Officer Emma Walmsley is looking to do more deals as the British drugmaker doubles down on its return to cancer medicines.
GSK To Buy US-Based Stomach Cancer Drug Developer For Over $1 Billion
GSK's $1 billion acquisition of IDRx includes IDRX-42, a precision therapy for GIST. Phase 1/1b trial shows 53% ORR in early ...
GSK in advanced talks to purchase U.S. biotech IDRx, FT reports
GSK (GSK) is in advanced discussions to purchase privately-owned U.S. biotech IDRx, which is working on a treatment for rare gastrointestinal ...